380 related articles for article (PubMed ID: 28122118)
1. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
Meaney CJ; Beccari MV; Yang Y; Zhao J
Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
[TBL] [Abstract][Full Text] [Related]
2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
[TBL] [Abstract][Full Text] [Related]
3. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
[TBL] [Abstract][Full Text] [Related]
4. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
5. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
Linder KE; Krawczynski MA; Laskey D
Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
[TBL] [Abstract][Full Text] [Related]
6. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
8. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
9. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
10. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
11. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
Henneman A; Guirguis E; Grace Y; Patel D; Shah B
Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review.
Beccari MV; Meaney CJ
Core Evid; 2017; 12():11-24. PubMed ID: 28356904
[TBL] [Abstract][Full Text] [Related]
14. Sodium zirconium cyclosilicate in hyperkalemia.
Packham DK; Rasmussen HS; Lavin PT; El-Shahawy MA; Roger SD; Block G; Qunibi W; Pergola P; Singh B
N Engl J Med; 2015 Jan; 372(3):222-31. PubMed ID: 25415807
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
Packham DK; Kosiborod M
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):567-73. PubMed ID: 26998854
[TBL] [Abstract][Full Text] [Related]
16. [Hyperkalemia : what can we expect from new potassium-lowering drugs?].
Schmitt R
Internist (Berl); 2015 Jul; 56(7):779-83. PubMed ID: 26062687
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia.
Rydell A; Thackrey C; Molki M; Mullins BP
Ann Pharmacother; 2023 Nov; ():10600280231209968. PubMed ID: 37953506
[TBL] [Abstract][Full Text] [Related]
18. Patiromer for the treatment of hyperkalemia.
Colbert GB; Patel D; Lerma EV
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):563-570. PubMed ID: 32511052
[TBL] [Abstract][Full Text] [Related]
19. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study.
Rafique Z; Liu M; Staggers KA; Minard CG; Peacock WF
Acad Emerg Med; 2020 Jan; 27(1):54-60. PubMed ID: 31599043
[TBL] [Abstract][Full Text] [Related]
20. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
